Prognosis of Resection and Radiotherapy in the Treatment of Intrahepatic Cholangiocarcinoma Patients

Comparison of Resection and Radiotherapy in the Prognosis of Intrahepatic Cholangiocarcinoma Patients

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01914289

Enrollment

200

Registered

2013-08-02

Start date

2011-01-31

Completion date

2016-04-30

Last updated

2016-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrahepatic Cholangiocarcinoma

Keywords

Intrahepatic Cholangiocarcinoma, Prognosis, Resection, Radiotherapy

Brief summary

The purpose of this study is to confirm that prognosis of Intrahepatic Cholangiocarcinoma (ICC) with resection and radiotherapy ,to find which is safe and effective treatment.

Detailed description

Intrahepatic Cholangiocarcinoma (ICC), the second most common primary liver cancer and constitutes 10% of primary liver malignancies. Current therapies for the treatment of ICC are ineffective and the role of liver transplantation is not well defined. This study reviews our experience with this tumor and looks for preoperative and pathologic indices that may help determine long term prognosis

Interventions

PROCEDUREResection

RADIATIONRadiotherapy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

17 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Male or female patients \> 17 years and \<=60 years of age. confirmed case (patients with ICC) Tumors can be radical removed and resection volume was ≤50%. Criteria of liver function: Child A level, serum bilirubin ≤ 1.5 times the upper limit of normal value,alanine aminotransferase and aspartate aminotransferase ≤ 2 times the upper limit of normal value. No dysfunction in major organs; Blood routine, kidney function, cardiac function and lung function are basically normal. Hbg ≥ 90g/L, WBC ≥ 3.000 cells/mm³,platelets ≥ 80.000 cells/mm³. Karnofsky Performance Score performance over 60. Patients who can understand this trial and have signed information consent.

Exclusion criteria

* Patients who have undergone previous treatment by Resection or Radiotherapy. Patients with apparent cardiac, pulmonary, cerebronic and renal dysfunction, which may affect the treatment of liver cancer. Patients with other diseases which may affect the treatment mentioned here. Patients with medical history of other malignant tumors. Subjects participating in other clinical trials. Extrahepatic metastasis, portal vein or other major vascular involvement. liver function: Child B C. Patients would not sign the consent to the trial.

Design outcomes

Primary

Measure	Time frame
the overall survival rate of each group	3 years

Countries

China

Contacts

Primary ContactLi Aijun, MD

ajli62@gmail.com86-21-81875531

Backup ContactYuan Hang

yuanhang8106@163.com86-21-81875531

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026